News

REMINDER - Marketing stop of Depakine (sodium valproate) 300 mg/5 ml syrup: beware of medication errors

As announced in December 2024, Sanofi Belgium has decided to stop marketing Depakine 300 mg/5 ml syrup as of 28 April 2025. Depakine's other oral liquid formulation, the 300 mg/ml oral solution, will remain available in Belgium. As the latter is more concentrated than the syrup and dosed with a different device, patients, healthcare professionals and parents need to be informed and prepared to avoid potential medication errors.

FAMHP joins Instagram!

To better inform and raise awareness among Belgian citizens, the FAMHP launches its Instagram account where content suited to this platform will be shared: infographics, practical tips, news on medicines and healthcare products, and much more.

Call for Belgian laboratories to apply as EU reference laboratories in the field of in vitro diagnostic medical devices

The European Commission has issued a second call for Member State laboratories to submit applications to become a European Union reference laboratory for in vitro diagnostic medical devices. The designation of these laboratories is provided for in Article 100 of Regulation (EU) 2017/746 on in vitro diagnostic medical devices.